CryoCell International Inc (CCEL) fair value: what the stock is really worth
As of Sep 29, 2026: fair value of CryoCell International Inc $9.85, price $4.05, upside +143.2%, quality 57 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch CryoCell International Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
60‑month range $2.71 – $11.36 · fair‑value band $7.30 – $13.84 · the $4.05 price screens below the $9.85 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 5 fiscal years are left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 27, 2026.
Follow CryoCell International in your weekly email
Every Wednesday you see whether CryoCell International is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Cryo-Cell International, Inc. engages in cord blood and cord tissue cryopreservation services in the United States.
Show more
Cryo-Cell International, Inc. engages in cord blood and cord tissue cryopreservation services in the United States. The company offers cellular processing and cryogenic storage for family use, primarily for collection and preservation of umbilical cord blood, and tissue stem cells; and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. It is also involved in the manufacturing of PrepaCyte CB processing system units for processing umbilical cord blood stem cells. In addition, the company provides cold storage services to third-party pharmaceutical companies and medical institutions. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. The company was incorporated in 1989 and is headquartered in Oldsmar, Florida.
Stock analysis
CryoCell International Inc (CCEL) currently trades at $4.05, while our model-based Fair Value estimate is $9.85, implying the stock looks roughly 58.9% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $11.76 per share, and 14 of the 14 models we run sit above the $4.05 price.
Bear case: the Earnings-Based group reads lowest at $4.71, and 0 of the 14 models stay below the price. Evidence for this calculation is medium.
Scenario range: $7.30 (bear) to $13.84 (bull), the price of $4.05 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 57/100 (solid quality), in the Healthcare sector.
Weak Growth: Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
CryoCell International Inc reported revenue of $31.6M in FY2025 versus $28.9M in FY2021, a compound +2.2%/yr. Reported net income was −$2.4M in FY2025.
Key figures
Market cap $32.7M · P/S ratio 1.03 · EPS (TTM) $−0.3100 · Dividend yield 10.1% · Net margin −7.7% · Return on equity 129% · Return on assets (EBIT) 1.2% · Operating margin 15.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 47 out of 100 (low confidence).
What moves the price
The share trades about 13% below its 52-week high and 40% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 21% fair-value upside, at 143%, CCEL screens cheaper than that median.
Fair Value models
Bear $7.30Fair Value $9.85Bull $13.84
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Revenue growth 1 year
−1.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.3%
Start year 2020 (pandemic). Over 10 years: +4.1% a year
Revenue growth 29 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.8%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
17.8% (2018) → −39.3% (2023)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−10.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about −12.4% a year for the price.
Compare CryoCell International Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 249 stocks
Beats the industry median on 7/11 measures
Overall it ranks above its industry peers.
Valuation
Quality Score56 · Above median
Fair Value upside+143.2% · Top 25%
Profitability
Return on equity (TTM)Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets−0.1% · Bottom 25%
Net margin (TTM)−7.9% · Bottom 25%
Operating margin (TTM)15.4% · Top 25%
Growth and dividend
Revenue growth−1.9% · Bottom 25%
Dividend yield (TTM)10.1% · Top 25%
Balance sheet
Debt / equityNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
P/BNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (TTM)1.05× · Cheaper than median
P/FCF6.2× · Cheapest 25%
EV/EBITDA46.5× · Priciest 25%
PEG1.34× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)100· sector 33
FUTURE (revenue growth)0· sector 28
PAST (return on equity)0· sector 31
HEALTH (low debt)0· sector 89
DIVIDEND (yield)100· sector 41
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "CryoCell International Inc Fair Value". https://www.fairvalue-calculator.com/stock/CCEL
Frequently asked questions
Is CryoCell International Inc (CCEL) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of $9.85 versus a price of $4.05, about +143% upside (undervalued).
What is the fair value of CCEL?
Our model-based fair value for CryoCell International Inc is $9.85 (as of Sep 27, 2026), built from audited fundamentals. The current price: $4.05.
What is the quality score of CCEL?
CryoCell International Inc has a Quality Score of 57/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for CryoCell International Inc (CCEL)?
Our model-based price target is the fair value of $9.85 (as of Sep 27, 2026) from 14 valuation models. Cautious scenario $7.30, optimistic scenario $13.84. It is a calculation from audited fundamentals, not an analyst target.
What is the CryoCell International Inc stock forecast for 2026?
Our models put fair value at $9.85, about +143% upside versus a price of $4.05 (undervalued). Cautious scenario $7.30, optimistic scenario $13.84. The calculation is refreshed regularly with new filings.
What is the revenue of CryoCell International Inc (CCEL)?
CryoCell International Inc reported trailing-twelve-month revenue of about $31.1M (latest available figure, as of Sep 27, 2026).
Does CryoCell International Inc pay a dividend?
CryoCell International Inc currently shows a dividend yield of about 10.12% relative to its recent price (as of Sep 27, 2026).
What growth is priced into CryoCell International Inc (CCEL)?
For today's price to be fair in a discounted-cash-flow model, CryoCell International Inc would have to grow free cash flow by -10.3 % per year for five years (discount rate 8.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +0.3 % per year. As of Sep 27, 2026.
What discount rate (WACC) does the fair value of CCEL use?
Our models discount CryoCell International Inc at 8.6 %: a base by market capitalisation (nano), damped by beta 0.52, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For CryoCell International Inc that is -10.3 % per year a year over ten years, using the same discount rate (8.6 %) and the same formula as our fair value.
How much growth has CryoCell International Inc (CCEL) delivered so far?
Over the past 5 years revenue at CryoCell International Inc grew +0.3 % a year. The price currently implies -10.3 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of CryoCell International Inc (CCEL) growing?
The median revenue growth in the sector is +4.3 % a year. That is the yardstick for the growth priced into CryoCell International Inc (-10.3 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of CryoCell International Inc (CCEL)?
The free-cash-flow yield on the price is 16.06 %: that much free cash flow CryoCell International Inc produces per unit of market value. When it exceeds the discount rate of our models (8.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of CryoCell International Inc (CCEL)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For CryoCell International Inc it is $9.85 per share (as of Sep 27, 2026), against a price of $4.05. It is the blended result of 14 valuation models (cash flow, earnings, asset, dividend).
Is CryoCell International Inc stock overvalued or undervalued in 2026?
As of Sep 27, 2026, CCEL trades below its calculated fair value: price $4.05, fair value $9.85, a gap of about +143% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CCEL?
No. The price is what the market pays today ($4.05); the fair value is what the company's own numbers justify ($9.85). For CryoCell International Inc the two are $5.80 per share apart. That gap is exactly why we show both numbers side by side.
How much is CryoCell International Inc worth?
The market values CryoCell International Inc at about $32.7M (market capitalisation, as of Sep 27, 2026). Per share that is $4.05; our models calculate a fair value of $9.85 per share.
What do the bullish and bearish scenarios say about CCEL?
Our models span a range for CryoCell International Inc: cautious scenario $7.30, base $9.85, optimistic $13.84 per share (as of Sep 27, 2026, price $4.05). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of CCEL?
The PEG ratio of CryoCell International Inc is 1.34 (P/E divided by earnings growth, as of Sep 27, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of CryoCell International Inc (CCEL)?
Balance-sheet figures for CryoCell International Inc (as of Sep 27, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 57/100, which measures business quality independently of the share price.
How far is CCEL from its 52-week high?
CryoCell International Inc trades at $4.05, about 13% below its 52-week high of $4.64 and 40% above the low of $2.89 (as of Sep 29, 2026). Distance from the high says nothing about value: that is what the fair value of $9.85 is for.
Which stocks are comparable to CryoCell International Inc?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, Tenet Healthcare Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is CryoCell International Inc stock attractive at the current price?
The data as of Sep 27, 2026: price $4.05, calculated fair value $9.85 (+143%), Quality Score 57/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CCEL calculated?
We run CryoCell International Inc through 14 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $9.85, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. CryoCell International Inc currently trades 59 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of CryoCell International Inc (CCEL)?
The closing price on Sep 29, 2026 was $4.05. Our model-based fair value is $9.85, about +143% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with CryoCell International Inc right now?
The price is below even our cautious bear case ($7.30). The market is more pessimistic than our downside scenario. Solid quality (57/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range ($7.30 to $13.84) leaves room in how you read the outcome.
Key figures of CryoCell International Inc
How large is the market capitalisation of CryoCell International Inc (CCEL)?
The market capitalisation of CryoCell International Inc is $32.7M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of CryoCell International Inc (CCEL)?
The price-to-sales ratio of CryoCell International Inc is 1.03 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of CryoCell International Inc (CCEL)?
Earnings per share at CryoCell International Inc are $−0.3100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of CryoCell International Inc (CCEL)?
The dividend yield of CryoCell International Inc is 10.1%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of CryoCell International Inc (CCEL)?
The net margin of CryoCell International Inc is −7.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of CryoCell International Inc (CCEL)?
The return on equity (ROE) of CryoCell International Inc is 129% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of CryoCell International Inc (CCEL)?
On an EBIT basis the return on assets of CryoCell International Inc is 1.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of CryoCell International Inc (CCEL)?
The operating margin of CryoCell International Inc is 15.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at CryoCell International Inc (CCEL)?
Revenue at CryoCell International Inc is growing −1.9% versus a year earlier (3y avg +1.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at CryoCell International Inc (CCEL)?
Earnings per share at CryoCell International Inc are growing +72.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does CryoCell International Inc (CCEL) carry?
The net debt of CryoCell International Inc is $2.9M (fiscal year 2025, ≈ 0.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch CryoCell International Inc in the live analysis
One click puts CryoCell International Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Some data
Sep 27, 2026